This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Hepatocyte nuclear factor 1-alpha.
Binds to the inverted palindrome 5'- GTTAATNATTAAC-3'. .
Human | |
---|---|
Gene Name: | HNF1A |
Uniprot: | P20823 |
Entrez: | 6927 |
Belongs to: |
---|
HNF1 homeobox family |
HNF1 homeobox A; IDDM20; LFB1transcription factor 1, hepatic; LF-B1, hepatic nuclear factor (HNF1), albuminproximal factor; MODY3; TCF1hepatic; Transcription factor 1
Mass (kDA):
67.356 kDA
Human | |
---|---|
Location: | 12q24.31 |
Sequence: | 12; NC_000012.12 (120977683..121002512) |
Liver.
Nucleus.
One of the most researched proteins found in the human body is the HNF1A gene. Researchers from all over the world are submitting their findings to the HNF1A Marker database in order to understand how this gene can be used in the study of various cancers. The results are valuable for species, applications, and other samples. In addition to permitting researchers to submit their research findings, Boster also provides product credits to researchers.
A study published in Molecular Cell revealed that LSCC cells reduced HNF1A/AS1 in a way similar to normal lung function. This suggests that HNF1A-AS1 may be an lncRNA which suppresses tumors in LSCC , and could also regulate EMT. These findings could lead to new ways to treat LSCC.
HNF1A–AS1 gene expression was found in LSCC tissues and cells. This was associated with the tumorigenicity, cervical lymph node metastasis and cervical lymph node metastasis. In addition, the expression of HNF1A-AS1 was reduced in primary LSCC tissues and metastatic cervical lymph nodes. The expression of HNF1A in metastatic and primary cervical lymphodes was minimal despite its potential role in the development of LSCC. Because of its low copy count of DNA and poor reproducibility, in situ hybridization wasn't a good choice for detection of HNF1A gene activity. However, RTQPCR is an effective tool for determining HNF1A gene activity in LSCC cells.
Furthermore, the overexpression of HNF1A-AS1 inhibited the proliferation of LSCC cells. This methylation occurred more frequently in lymph nodes of metastatic cervical cancer than in normal tissue. Therefore, this decrease in HNF1A could be a tumor suppressor. Thus, this marker could play a crucial role in LSCC progression.
RNAiso Plus was used to detect the expression of HNF1A/AS1 within human cells. The RT-qPCR process used RNAiso Plus, PrimeScript(tm) RT Master Mix, Takara Bio, Inc.'s TB Green(tm) Premix Ex Taq II. The LSCC and HNF1A markers in Boster Bio are highly linked to one another.
In a study involving the LSCC cells we discovered that the expression of HNF1A-AS1 was reduced and modified in metastatic cervical lymph nodes. Using a reverse transcription-quantitative PCR method with GAPDH as an internal control, we were able to detect HNF1A-AS1 methylation in the LSCC tissues and in adjacent non-tumor tissues. We also performed methylation analyses by using the same method on 530 head and neck squamous cell carcinoma and 50 normal controls.
The HNF1A -AS1 inhibits tumorigenesis as well as inhibits cell invasion and migration. We used the same method for the HNF1A and LSCC cell lines, and we discovered that these cells were more sensitive to serum starvation than the control group. We also assessed the size of the tumor as well as the ability to invade of the cells.
The study also revealed that lncRNA expression in vivo reduces the growth of gastric tumors and lymph nodes. HNF1A, AS1 expression was observed to reduce the growth of hepatocellular cancer cells using RNA-based. The effects of HNF1A/AS1 on cervical lymph node metastasis also assessed in a separate study. This study indicates that HNF1A/AS1 regulates Vimentin Snail1/Slug2, and N-cadherin.
We employed a high affinity antigen against HNF1A to confirm the results. Boster provides primary antibodies validated on Western Blotting, Immunohistochemistry, and ELISA. In addition, we used the boster anti-LSCC antibody to perform semi-quantification. The antibody is available in the Boster Bio database. This antibody is compatible with the human cell line.
In a recent study, researchers found that the HNF1A-AS1 gene is not being regulated in primary LSCC and metastatic lymph nodes. This could indicate a significant role in the progression of LSCC since the gene is negatively linked with EMT. Boster Bio has created a new poster to explore the possibilities of using the HNF1A marker for LSCC.
The Boster HNF1A marker has been validated with multiple platforms, including well-known positive and negative samples. The antibodies were evaluated for specificity and high affinity. Boster recognizes that high-quality antibodies are essential to the successful detection of hepatocellular cancer. That's why it has developed a system to reward scientists who evaluate its products.
The Peruvian population showed unique mutations, with the major class being Insertions/Deletions. More than half of the samples did not show mutations at hotspots related to hepatocellular cancer. These results confirm NANOG's stemness factor and the decline of Hippo axis. These findings confirm the specificity and rarity of Peruvian Hepatocellular Cancer.
The study uncovered the pseudogenes of 174 and 1.77% HNF1A-associated transcripts from the two gene expression platforms. This helps explain liver toxicity. The DEGs identified in this study are prominently expressed in Hepatotoxicants. Hepatotoxicants influenced the expression of 174 of them. The complete list of these transcripts can be found in Supplementary Excel File S4.
The HNF1A gene is an oncogenic transcription factor that regulates the growth of cells within the body. The development of tumors occurs when cancer cells multiply. This is known as staging. The more advanced the disease and the more advanced the stage. This information aids in determining the best treatment. Cancers are typically classified into two types surgical stage and pathologic stage.
The HNF1A gene is found in a variety of tumor types, including laryngeal cancer. The gene regulates many transcription factors. It is expressed as molecules on the cell surface that aids doctors in identifying cancerous cells. HNF1A-producing cancers are usually aggressive and can lead to the death rate to be high. About 5% of the people in the world have the HNF1A gene.
A meta-analysis of 22 consecutive case series examined the effects of cetuximab on oncologic control of patients suffering from locally advanced laryngeal cancer. The combination of cetuximab and radiation therapy was associated with a significantly better progression-free survival rate compared with concurrent chemotherapy therapy. Concurrent chemoradiation therapy or radiotherapy is still recommended for patients suffering from larynx cancers that are locally advanced.
In recent times, the expression of non-coding circular RNAs has been found to be associated with a poor prognosis in laryngeal cancer. We investigated the role of miR-154 in LSCC and discovered that it decreased the growth of LSCC cells. We also looked for an association between miR-154 and glycolysis, which is a gene involved in glycolysis.
A retrospective study of 59 patients suffering from laryngeal cancer found that patients with a high amount of HNF1A gene expression were more likely to have a diagnosis of the disease. There was also significant intra-tumor heterogeneity. There was more than four-fifths of the breakpoints being located within the central regions.
The most effective way to use the HNF1A marker in laaryngeal cancer is to base it on tumor samples that contain high levels of the underlying RNA. It is thought that the HNF1A AS1 gene acts as a tumor suppressor lncRNA. It regulates EMT which is a key factor in the progression of laryngeal cancer.
HNF1A was discovered to be deregulated in primary LSCC tissues, and hypermethylated due to metastatic cervical lymph nodes. This is believed to be due to the hypermethylation of the promoter region. HE staining confirmed HNF1A gene expression within LSCC tissues as well as adjacent normal tissues. The HNF1A gene methylation status was assessed in the heads and neck Squamous Cell Cancer samples as well as fifty adjacent normal tissues.
HNF1A is not present in all cases. However, it has been associated with poor pathological differentiation in LSCC cells. Aberrant methylation may also play an important role in the silencing of genes. A2d1+ cells also display an extremely high degree of self-renewal. They are also chemoresistant.
PMID: 1707031 by Bach I., et al. Cloning of human hepatic nuclear factor 1 (HNF1) and chromosomal localization of its gene in man and mouse.
PMID: 7900999 by Bach I., et al. More potent transcriptional activators or a transdominant inhibitor of the HNF1 homeoprotein family are generated by alternative RNA processing.
*More publications can be found for each product on its corresponding product page